CANCER patients could miss out on access to nine new medicines that are due to be considered for subsidy by the PBAC next month.  Many of the medicines, which can cost patients tens of thousands of dollars, have already been rejected multiple times even though they are subsidised overseas. The medicines up for review include Inlyta (Axitinib), an advanced renal cell cancer treatment that costs up to $9,000 per course and Avastin (bevacizumab), which is used to treat patients with advanced ovarian cancer. Lung cancer medicine Xalkori (crizotinib), which costs $86,000/course of treatment, will also be up for review. For more details, go to: http://www.heraldsun.com.au/news/national/fears-aussie-cancer-patients-may-miss-out-on-drugs/story-fni0xqrb-1226739212049